Coloplast stock

COLO.B · Nasdaq Copenhagen · DKK

Compare Coloplast
kr 510.20Change from previous close: +0.43%Absolute change: +kr 2.20

Close · November 16, 2026

Price history

−11.18% over the period

1 year: from kr 574.00 (November 17, 2025) to kr 509.80 (November 16, 2026), −11.18%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026kr 509.80
October 30, 2026kr 482.30
September 30, 2026kr 417.90
August 31, 2026kr 458.80
July 31, 2026kr 429.40
June 30, 2026kr 372.30
May 29, 2026kr 395.80
April 30, 2026kr 393.90
March 31, 2026kr 436.40
February 27, 2026kr 488.00
January 30, 2026kr 536.00
December 30, 2025kr 546.40
November 28, 2025kr 580.80
November 17, 2025kr 574.00

At a glance

  • The company

    Develops and sells intimate healthcare products and services, including ostomy, continence, wound and voice and respiratory care

  • Latest results

    Quarter to September 30, 2026 · EPS kr 5.67 (estimate kr 5.82)

TickerLandia's take on Coloplast

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 369.70
52-wk highkr 591.60

−13.76% from the 52-week high

Analysts · 21 analysts

Average targetkr 473.81−7.13% vs. price

Buy 3 · Hold 15 · Sell 3 · Hold

TickerLandia Fingerprint: Coloplast

Compared with similar companies: very high dividend.

Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Coloplast is priced as in the past and cheaper than similar companies

On the latest fiscal year's earnings (2026), Coloplast's P/E today is 37.4, in line with the median of its last 10 fiscal years (35.7; between 28.6 and 51.0 from 2017 to 2026). Coloplast's P/E (trailing 12 months): 37.2, −11% against the median of a group of 10 similar companies (41.9).

P/E compared with its history

Compared with 10 similar companies

Coloplast's metrics compared with similar companies
MetricColoplastPosition in the groupBand
P/E (trailing 12 months)37.2Middle
Forward P/E18.8Middle
Operating margin25.7%High
ROE20.2%High
Debt/equity1.51High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Coloplast. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 7.46B

Latest quarter · Q3 2026

Net income

kr 1.19B

Latest quarter · Q3 2026

Quarterly net margin

15.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
kr 114.49B
P/E
37.2
EPS
kr 13.64
Volume
295.52K
Daily trading
€28.75M
Dividend yield
0.98%
Last ex-dividend on May 18, 2026

How Coloplast is changing

All results
  • Revenue grew 8.3% a year on average over the last 5 years

  • Operating margin fell from 28.0% to 25.7%

  • Profits turn into cash: free cash flow equal to 115% of net income

Returns

Coloplast returns with dividends

kr 1,000 invested in Coloplast 5 years ago, on November 16, 2021, would be worth kr 502 today with dividends reinvested: −49.80% in total, −12.88% per year. On price alone it would be kr 437 (−56.28%).

PeriodColoplastkr 1,000 becomes
1 month+7.96%kr 1,080
6 months+27.77%kr 1,278
Year to date−6.70%kr 933
1 year−7.30%kr 927
3 years−23.45%kr 765
5 years−49.80%kr 502
10 years+52.28%kr 1,523

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Coloplast: technical analysis

Coloplast shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 56.9% below its all-time closing high (kr 1,182.50, August 5, 2021).

Trend
No clear trend
RSI (14 sessions)
65
Between 30 and 70
vs 200-session average
+16.78%

Support and resistance

Price areas where Coloplast has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 587.30+15.11%2 touches, last on January 13, 2026
  2. Resistancekr 534.20+4.70%3 touches, last on November 5, 2026
  3. Last pricekr 510.20
  4. Supportkr 446.70−12.45%4 touches, last on November 3, 2026
  5. Supportkr 419.56−17.77%8 touches, last on September 24, 2026
  6. Supportkr 392.37−23.10%3 touches, last on July 23, 2026

Volatility and risk

Volatility (60 sessions, annualised)
27.3%
Largest fall in the last year
−36.81%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Coloplast: seasonality

Average monthly price change over 27 years

+2.0%Jan+1.9%Feb+1.4%Mar+2.9%Apr−1.0%May−1.0%Jun+3.2%Jul+1.0%Aug−1.0%Sep+2.6%Oct+0.5%Nov+0.1%Dec

Over the last 27 years, the strongest month for Coloplast has been July: +3.19% on average, positive in 20 years out of 27. The weakest has been September: −1.04% on average, positive in 13 years out of 27. November, the current month, has been positive in 12 years out of 26 (+0.50% on average).

Show chart data
MonthAverageMedianPositive years
January+1.96%+1.88%17 of 26
February+1.95%+2.33%17 of 27
March+1.36%+0.84%16 of 27
April+2.92%+3.13%19 of 27
May−0.99%+0.48%14 of 27
June−0.96%−1.92%11 of 27
July+3.19%+3.20%20 of 27
August+0.98%0.00%12 of 27
September−1.04%−0.10%13 of 27
October+2.61%+1.53%17 of 27
November+0.50%0.00%12 of 26
December+0.13%−0.30%11 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Coloplast and its competitors

SenSura ostomy appliances, Conveen urine bags, SpeediCath catheters, Peristeen irrigation systems, Biatain and Comfeel wound dressings and the Provox voice prosthesis are among the products through which Coloplast sells intimate healthcare products and services. Its range spans ostomy, continence, wound care, urology and voice and respiratory care, sold in Denmark, the United States, the United Kingdom, France and other markets abroad. The company also offers Brava ostomy accessories and Tracoe tracheostomy care products.

Headquarters
Humlebæk, Denmark
Employees
17,270
Founded
1954
Chief executive
Gavin Wood
Coloplast and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ColoplastCOLO.B$16.93B25.7%37.2+27.77%
SartoriusSRT$19.89B17.8%79.3+37.44%
Straumann HoldingSTMN$20.69B24.7%47.1+30.05%
Sartorius Stedim BiotechDIM$24B19.2%67.0+44.45%
AlconALC$35.8B12.9%57.3+23.24%
Ypsomed HoldingYPSN$6.77B36.2%34.3+44.57%

Same industry or related industries, similar size. Compare Coloplast with its competitors · Full profile